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ORIGINAL RESEARCH
Abstract: Clinical studies indicate that adjunctive treatment with the antidepressant
drug mianserin, a 5-hydroxytryptamine (5-HT)2A/C receptor antagonist and an α2- and
α1-adrenoceptor antagonist, may enhance the effect of conventional antipsychotic drugs in
schizophrenia, in particular on negative symptoms such as withdrawal retardation, akathisia,
and some aspects of cognitive impairment. Here, we have examined the effect of mianserin in
combination with the selective dopamine (DA) D2/3 receptor antagonist raclopride on
conditioned avoidance response (CAR), a preclinical test of antipsychotic efficacy with high
predictive validity; catalepsy, a preclinical test of extrapyramidal side effect liability; and DA
output in the medial prefrontal cortex (mPFC) and the nucleus accumbens (NAC), respectively.
Mianserin (5 mg/kg intraperitoneal) significantly enhanced the suppressant effect of a low
dose of raclopride (0.1 mg/kg subcutaneous) on CAR without any increase in catalepsy.
Administration of raclopride to rats pretreated with mianserin resulted in a large enhancement
of DA output in the mPFC and, at the same time, a small but significant reduction in the
raclopride-induced DA output in the NAC. These experimental results indicate that adjunctive
treatment with mianserin to a typical D2 antagonist generates an atypical antipsychotic profile.
Keywords: adjunctive mianserin, typical antipsychotic drugs, dopamine, prefrontal cortex,
atypicality
Introduction
The clinical effect of conventional (typical) antipsychotic drugs (APDs) has been
largely ascribed to their dopamine (DA) D2 receptor blocking action (Carlsson 1988).
However, although these drugs, eg, haloperidol, are usually effective against positive
symptoms, they show less efficacy against negative and cognitive symptoms
(Carpenter 1996; Volavka et al 1996; Leucht et al 1999). Clinically effective doses
of typical APDs generate about 70%–85% D2 receptor occupancy in brain, but a
D2 receptor occupancy above 80% has been associated with a relatively high risk of
extrapyramidal side effects (EPS) (Farde et al 1992). In contrast, some, but not all, of
the so-called second generation (atypical) APDs may be clinically effective at lower
D2 occupancy in brain, with clozapine around 45% (Nordstrom 1995), and are
associated with a significantly reduced, and in the case of clozapine essentially
abolished, EPS liability (Safferman et al 1991). Yet, clozapine shows superior efficacy
in treatment-resistant schizophrenia, and moreover, several atypical APDs have been
claimed to show improved efficacy against negative and cognitive symptoms (Meltzer
1995; Davis et al 2003). Clozapine possesses a complex pharmacology, acting as an
antagonist not only at several DA receptors (ie, D2, D3, and D4 receptors) but also at,
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for example, 5-HT2A and 5-HT2C receptors, α1- and α2-
adrenoceptors, and muscarinic and histaminergic (H1)
receptors. Moreover, clozapine may function as a partial
agonist at D1 and 5-HT1A receptors (Schotte et al 1996),
raising the possibility that several receptor affinities may
contribute to the atypical APD profile (Svensson 2003). By
contrast, the alternative D2 receptor “fast-off” hypothesis
of Kapur and Seeman (2001) applies only to clozapine and
quetiapine and is inconsistent with the “slow” off-rate of
most atypical APDs (Meltzer et al 2003).
Previous clinical augmentation trials involving
conventional APDs may help elucidate this issue. Thus, the
addition of ritanserin, a 5-HT2A/C antagonist, was found to
enhance the antipsychotic effect of typical APDs, in
particular negative symptoms (Gelders et al 1986, Gelders
1989). Other clinical studies have shown that adjunctive
treatment with idazoxan, a selective α2-adrenoceptor
antagonist, can enhance the efficacy of conventional APDs
in treatment-resistant schizophrenia (Litman 1993; Litman
et al 1996), including both positive and negative symptoms
and total Brief Psychiatric Rating Scale score. Moreover,
mianserin, a clinically effective antidepressant drug, which
acts as an antagonist at 5-HT2A/C receptors, α2- and α1-
adrenoceptors, and muscarinic and histaminergic (H1)
receptors (Pinder 1991), has also been found to enhance
the clinical effect of typical APDs, particularly concerning
negative symptoms such as withdrawal retardation,
akathisia, and some aspects of cognitive dysfunction (Itil et
al 1974; Mizuki et al 1990, 1992; Poyurovsky 1999;
Grinshpoon et al 2000; Shiloh et al 2002; Poyurovsky et al
2003). This generates a clozapine-like clinical effect
(Lindstrom 2000) as well as a combined receptor binding
profile relatively similar to that of clozapine (cf Pinder 1991;
Bymaster et al 1996).
Several experimental studies may contribute to clarify
the neurobiological mechanisms of particular importance
in this respect. Thus, clozapine as well as other atypicals
have, in contrast to typical APDs, been found to
preferentially enhance DA outflow in the prefrontal cortex
(Imperato and Angelucci 1989; Moghaddam and Bunney
1990; Nomikos et al 1994; Kuroki et al 1999; Westerink et
al 2001). As previous experimental results using both a
neurodevelopmental model and the phencyclidine model of
schizophrenia inter alia have indicated an impaired
prefrontal DA projection in this disease (see Weinberger
and Lipska 1995; Svensson et al 1995; Egan and Weinberger
1997; Egan et al 2001), the selective augmentation of
prefrontal DA output by clozapine and other atypicals may
allow for restoration of a pathophysiological deficit in
schizophrenia, tentatively related to cognitive and/or
negative symptoms (see Svensson 2003). Both the addition
of ritanserin and idazoxan to the selective D2/3 antagonist,
raclopride, produced an enhanced suppression of the
conditioned avoidance response (CAR) in rodents, ie, an
antipsychotic-like effect, without any concomitant increase
in catalepsy (Wadenberg et al 1996; Hertel et al 1999), as
well as a preferential enhancement of prefrontal DA output
not seen with the D2/3 antagonist alone (Andersson et al 1995;
Svensson et al 1995; Hertel et al 1999). Since subsequent
behavioral (Wadenberg et al 1998) and biochemical
(Liégeois et al 2002) studies using the selective 5-HT2A
receptor antagonist M100907 produced similar results,
whereas 5-HT2C receptor blockage activates both cortical
and subcortical DA projections (Di Matteo et al 2000; Gobert
et al 2000), the preferential enhancement of prefrontal DA
efflux by atypicals may be associated with blockade of 5-
HT2A rather than 5-HT2C receptors. Thus, clinical as well as
preclinical, correlative behavioral, and biochemical studies
indicate that an enhanced effect of typical D2 antagonists in
schizophrenia can be obtained by adding 5-HT2A- and/or
α2-receptor blockage and that this effect is indeed associated
with enhanced prefrontal DA output.
Here, we have experimentally investigated the effect of
combining raclopride and mianserin, which when given
alone increases DA output both in the medial prefrontal
cortex (mPFC; Tanda et al 1996) and in the nucleus
accumbens (NAC; Di Matteo et al 2000) on DA efflux in
both terminal areas of the mesocorticolimbic system, as well
as by correlative behavioral studies using the CAR paradigm
and additional assessment of catalepsy scores.
Materials and methods
Animals
Adult male BK1:WR (Wistar) rats weighing 300–390 g
(CAR), 270–310 g (catalepsy), or 230–390 g (microdialysis)
were used in all experiments. Animals arrived at least five
days prior to experimental use and were housed (4 per cage
[Makrolon IV]) in the animal facility under standard
laboratory conditions with a 12-h light/dark cycle. Rats
designated for microdialysis had lights on at 6.00 am,
whereas animals designated for behavioral experiments were
subjected to a reversed light/dark cycle, ie, lights off at
6.00 am. All experiments were performed between 8.00 am
and 6.00 pm. Food and water were available ad lib. AllNeuropsychiatric Disease and Treatment 2005:1(4) 367
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experiments were approved by, and conducted in accordance
with, the local Animal Ethics Committee (Stockholms Norra
och Södra Försöksdjursetiska Kommittéer) (permit
numbers N216/00, N11/00).
Conditioned avoidance response
A shuttle-box (530 mm × 250 mm × 225 mm) divided into
two compartments by a partition was used. The rats were
free to move from one compartment to the other via an
opening (75 mm × 75 mm) in the partition. Upon
presentation of the conditioned stimulus (CS), 80 dB white
noise (White Noise Generator, Lafayette 1501, Lafayette,
IN, USA), the rat had 10 s to avoid the unconditioned
stimulus (USC), an intermittent electric shock in the grid
floor of approximately 0.2 mA (intershock interval 2.5 s,
shock duration 0.5 s), by moving into the opposite
compartment. The following behavioral variables were
recorded: (1) avoidance (response to CS within 10 s); (2)
escape (response to CS + UCS); (3) escape failure (if the rat
was unable to respond to the shock within 50 s the trial was
terminated). The animals were trained for 5 consecutive
days, and were adapted to the shuttlebox 5 min before the
training session started. Each training session consisted of
20 trials randomly distributed over 15 min. All subsequent
pre-tests and experimental test sessions consisted of 10 trials
randomly distributed over 7.5 min. Experimental
manipulations were always preceded by a pre-test. The same
animals were tested repeatedly according to a change-over
design (Li 1964) serving as their own controls. Only rats
that showed at least 90% avoidance on the last day of training
were included in the experiments.
Catalepsy
Animals were placed on an inclined (60°) grid and,
excluding the first 30 s, the time the rat remained in the same
position was measured for a maximum of 2.5 min. The
catalepsy was scored from 0–5 according to the time (square
root transformation) the animal remained immobile (min):
0 = 0–0.08, 1 = 0.09–0.35, 2 = 0.36–0.80, 3 = 0.81–1.42,
4 = 1.43–2.24, 5 = ≥ 2.25 min; ie, if the rat remained
immobile for ≥ 2.25 min it was scored 5, etc (Ahlenius and
Hillegaart 1986).
Microdialysis
The probe implantation and dialysis procedure, as well as
the biochemical analyses, were similar to those previously
described (Hertel et al 1996). Anesthetized male BKl:WR
(Wistar) rats (B&K Universal, Sollentuna, Sweden; sodium
pentobarbital, 60 mg/kg, intraperitoneal [IP]) were
implanted with dialysis probes in the mPFC or NAC (AP:
+2.6, +1.4; ML: –0.6, –1.4; DV: –5.2, –8.2), respectively,
relative to bregma and dural surface (Paxinos and Watson
1998). Dialysis occurred through a semipermeable
membrane (AN69 Hospal) with an active surface length of
4 and 2.25 mm for mPFC and NAC, respectively. Dialysis
experiments were conducted approximately 48 h after
surgery in freely moving rats. The dialysis probe was
perfused with a physiological perfusion solution
(147 mmol/L sodium chloride, 3.0 mmol/L potassium
chloride, 1.3 mmol/L calcium chloride, 1.0 mmol/L
magnesium chloride, and 1.0 mmol/L sodium phosphate,
pH 7.4) at a rate of 2.5 µL/min set by a microinfusion pump
(Harvard Apparatus, Holliston, MA). Online quantification
of DA in the dialysate was accomplished by high pressure
liquid chromatography coupled to electrochemical detection.
The detection limit for DA was approximately 0.2 fmol/min.
The placement of the probe was later verified in slices
stained with neutral red.
Drugs
Mianserin (Sigma-Aldrich, Stockholm, Sweden) and
raclopride tartrate (Astra Zeneca, Södertälje, Sweden) were
dissolved in saline. Mianserin was subsequently adjusted
to pH ~ 6 (at a higher pH the drug precipitated) and
raclopride was adjusted to physiological pH (7.0–7.3).
Mianserin or saline was administered IP (1.0 mL/kg) and
raclopride or saline was administered subcutaneously (SC)
(1.0 mL/kg). The dose of mianserin was chosen based on
previous studies with mianserin in microdialysis (Tanda et
al 1996; Di Matteo et al 2000). The doses of raclopride used
(0.05–0.1 mg/kg SC) were chosen based on earlier
experiments, where no or only moderate effects on CAR
(Hertel et al 1999) and low, subtherapeutic (≤ 65%) D2
receptor occupancy (Wadenberg, Kapur, et al 2000) have
been observed. During microdialysis, administration of
drugs or vehicle was performed after stable outflow (< 10%
variation) of DA was obtained.
Statistics
Behavioral experiments. Statistical evaluation was
performed by means of the Friedman two-way analysis of
variance (ANOVA), followed by the Wilcoxon matched-
pairs signed-ranks test (CAR) or the Kruskal-WallisNeuropsychiatric Disease and Treatment 2005:1(4) 368
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one-way ANOVA, followed by the Mann-Whitney U-test
(catalepsy) (Siegel and Castellan 1988).
Microdialysis. Data were calculated as percent changes
of basal DA output over time. Baseline (= 100%) was defined
as the average of the last two (mPFC) or four (NAC)
preinjection values. Data were statistically evaluated using
two-way (treatment × time) ANOVA for repeated measures
followed by the Newman-Keuls test for multiple
comparisons.
Results
Conditioned avoidance response
Raclopride (0.05 or 0.1 mg/kg SC) produced a statistically
significant suppression of CAR 20 minutes after
administration, but not at later observation times (90 and
240 minutes). Pretreatment with mianserin (5 mg/kg IP 30
min before) produced a significant enhancement of the
suppression of CAR induced by raclopride (0.1 mg/kg)
compared with animals treated with raclopride alone.
Mianserin by itself had no effect on CAR. No significant
effects were observed at later observation times, and no
escape failures were recorded under any treatment condition;
ie, a decrease in avoidance responses was always
accompanied by a corresponding increase in escape
responses (Figure 1).
Catalepsy
Raclopride (0.1 mg/kg SC) alone, or in combination with
mianserin (5 mg/kg IP), did not produce any significant
catalepsy at any of the observation times. The administration
of a higher dose of raclopride (1.0 mg/kg SC) resulted in a
cataleptic response that peaked at 60 minutes after
administration. At this time point and dose of raclopride,
pretreatment with mianserin (5 mg/kg IP – 30 min) caused a
consistent, albeit not significant, decrease in catalepsy scores
compared with animals treated with raclopride alone
(Figure 2).
Microdialysis
The mean baseline concentration (fmol/min ± SEM) of DA
in the mPFC and the NAC was 0.44 ± 0.09 (n = 24) and
4.41 ± 0.61 (n = 24) fmol/min, respectively, (data not
corrected for in vitro dialysis probe recovery).
Administration of mianserin (5 mg/kg IP) alone, or in
combination with raclopride (0.1 mg/kg SC), resulted in a
significant increase in DA output in the mPFC, which was
significantly larger in the combination-treatment group
Figure 1 Effects of saline or mianserin (5 mg/kg IP) pre-treatment (30 min) on
saline – or raclopride (0.05 and 0.1 mg/kg SC) – induced effects in the conditioned
avoidance response test (a) 20 min, (b) 90 min, and (c) 240 min after saline or
raclopride administration. Each bar represents the median avoidance %
(± semi-interquartile range; n = 9 in all groups). Statistical evaluation was
performed by means of the Friedman two-way analysis of variance (ANOVA),
followed by the Wilcoxon matched-pairs signed ranks test. ANOVA Chi
2
(df = 5) = 35.5, p < 0.001. 
*p < 0.05, 
**p < 0.01 compared with respective control
(saline/saline or mianserin/saline). 
+p < 0.05 for comparisons between
saline/raclopride and mianserin/raclopride treatment group.
(a)
(b)
(c)
(Figure 3a). Administration of raclopride (0.1 mg/kg SC)
alone had no significant effect on mPFC DA output but
resulted in a significant increase in DA output in the NAC.
Pretreatment with mianserin (5 mg/kg IP) caused a small,
but significant reduction of the effect of raclopride
(0.1 mg/kg SC) on NAC DA output. Administration of saline
or mianserin (5 mg/kg IP) alone had no effect on NAC DA
output (Figure 3b).Neuropsychiatric Disease and Treatment 2005:1(4) 369
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Discussion
The major finding of the present study is that the addition
of mianserin to the selective D2/3 receptor antagonist
raclopride causes a significant enhancement of the
raclopride-induced suppression of CAR without increasing
catalepsy scores, providing experimental evidence for an
enhanced antipsychotic efficacy of the drug combination
compared with raclopride alone, yet without any increased
EPS liability. The relatively low doses of raclopride used,
that did not cause an effective antipsychotic-like effect when
given alone has been observed to generate a central D2
occupancy of about 50%–65% (Wadenberg, Kapur, et al
2000). Notably, about 80% D2 occupancy is necessary to
produce a suppression of the CAR of such magnitude that
it would predict sufficient antipsychotic activity, although
at this level of D2 occupancy catalepsy also begins to occur
(Wadenberg, Kapur, et al 2000). Thus, the adjunctive
treatment with mianserin allowed for a sufficient
Figure 3 Effects of saline or raclopride (0.1 mg/kg SC) administration on
dopamine (DA) output in (a) the medial prefrontal cortex
and (b) the nucleus accumbens (NAC) in animals pretreated with saline or
mianserin (5 mg/kg IP). Arrows indicate time injections. Each point represents
the mean percent (± SEM) change from baseline (n = 6 in all groups). Data were
analyzed using two-way (treatment × time) analysis of variance (ANOVA)
followed by the Newman-Keuls test for multiple comparisons.
(a) F(treatment; 3, 19) = 13.99, p < 0.001; F(time; 10, 190) = 53.68, p<0.001; and
F(treatment × time; 30, 190) = 16.31, p < 0.001. (b) F(treatment; 3, 20) = 10.11,
p > 0.001; F(time; 21, 420) = 37.22, p < 0.001; and F(treatment × time; 63, 420)
= 11.49, p < 0.001.
 *p < 0.05, 
**p < 0.01, 
***p < 0.001 for difference from saline/saline
treatment group. 
+p < 0.05, 
+++p < 0.001 for comparisons between saline
raclopride and mianserin/raclopride treatment group.
(a)
(b)
mL/kg
Figure 2 Effects of saline or mianserin (5 mg/kg, IP) pre-treatment (30 min) on
saline – or raclopride (0.1 and 1.0 mg/kg SC) – induced effects on catalepsy (a)
30 min, (b) 60 min, (c) 120 min, and (d) 240 min after saline or raclopride
administration. Each bar represents the median catalepsy score (± semi-
interquartile range; n = 8 in all groups). Statistical evaluation was performed by
means of the Kruskal-Wallis one way analysis of variance (ANOVA), followed by
the Mann-Whitney U-test. ANOVA Chi
2 (df = 5) = 11.75, p > 0.05.
 *p < 0.05,
**p < 0.01, ***p < 0.001 compared with respective control (saline/saline or
mianserin/saline).
(d)
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antipsychotic-like effect of raclopride even at a dose level
of raclopride that by itself was insufficient, but also clearly
below its EPS dose-range, ie, generating an atypical
antipsychotic profile. Since both treatments with the
selective 5-HT2A receptor antagonist M100907 and with the
selective α2-adrenoceptor antagonist idazoxan have been
found to potentiate the suppression of CAR by raclopride,
blockage of either one of these receptors, or both, by
mianserin may be causally related to the enhanced
antipsychotic-like effect.
Our results also demonstrate that the addition of
mianserin to the selective D2/3 receptor antagonist,
raclopride, induced a preferential increase in prefrontal DA
output, in contrast to the effect of the D2/3 antagonist alone
but analogous to the effect of clozapine and, to a varying
degree, most atypical APDs (cf Introduction), including
aripiprazole (Li et al 2004). As previously mentioned, this
biochemical effect may to a significant extent be related to
the 5-HT2A receptor antagonistic effect of mianserin.
However, given the fact that a similar, and even more potent,
enhancement of the raclopride-induced prefrontal DA efflux
has been observed by adjunctive treatment with idazoxan
(Hertel et al 1999), which also enhances the effect of typical
APDs in treatment-resistant schizophrenia (cf Introduction),
the potent α2-receptor antagonistic property of mianserin
may well be equally important in this regard. Indeed,
previous experimental evidence (Hertel et al 1999) indicates
that an increased prefrontal DA output per se may be causally
related to enhanced antipsychotic-like effect as assessed by
the CAR test. A recent study indicates that addition of
mianserin to typical APDs improves performance in
neurocognitive tests compared with the effect of typical
APDs alone (Poyurovsky et al 2003). Such a pro-cognitive
effect, if confirmed by other studies, may clearly be related
to an enhanced cortical DA output. Notably, this effect of
adjunctive mianserin may not be confined to the prefrontal
cortex alone, since recently mianserin, in full analogy with
clozapine, was shown to increase dialysate levels of DA
also in the parietal and occipital cortex (Valentini et al 2004).
A potential cognitive enhancing effect of adding mianserin
to conventional D2 antagonists seems important as the degree
of cognitive impairment largely determines treatment
outcome in schizophrenia, especially social functioning
(Green 1996; Harvey 1998).
In contrast to ritanserin or idazoxan, the addition of
mianserin to raclopride also caused a slight, but still
significant suppression of the raclopride-induced increase
in DA outflow in the subcortical brain region studied; ie,
NAC, an effect that in itself is secondary to the D2 receptor
blockade (see Carlsson 1988). Previous studies show that
both the α1-adrenoceptor antagonist prazosin and the
selective 5-HT2A receptor antagonist M100907 inhibit the
D2 receptor antagonist-induced increase in accumbal DA
release (Andersson et al 1995; Liégeois et al 2002) and,
moreover, that prazosin (Wadenberg, Hertel, et al 2000) in
similarity with M100907 (cf Introduction) also enhances
the CAR suppression induced by D2 antagonists. Thus,
both the 5-HT2A receptor antagonistic action and the
α1-adrenoceptor antagonistic effect of mianserin may, in
principle, contribute to the slight inhibition of the raclopride-
induced accumbal DA release observed in the present study
and, by inference, to the suppression of the CAR. Such a
mechanism may also have bearing on the overall anti-
psychotic efficacy of combining mianserin and typical D2
receptor antagonists in schizophrenia, albeit not necessarily
related to relief of negative symptoms. This notion gains
further support from both preclinical and clinical
observations. Thus, both prazosin (Mathé et al 1996) and
M100907 (Schmidt and Fadayel 1995) act to suppress
evoked, but not basal DA release in the NAC of experimental
animals, and clinical studies indicate that schizophrenic
patients display an enhanced evoked, but not basal
subcortical DA release (Laruelle et al 1996; Breier et al
1997).
In conclusion, several pharmacological properties of
mianserin, namely blockade of 5-HT2A receptors, α2- as well
as α1-adrenoceptors may contribute to its clinical effect
when added to typical D2 receptor antagonists in the
treatment of schizophrenia, which appears to include not
only an effect on negative symptoms, but also a reduction
in dysphoria, anxiety, akathisia, and potentially cognitive
dysfunction. Yet, the sedative effect of mianserin may, as in
the case of clozapine, largely be correlated with its histamine
H1 receptor antagonistic action, which may contribute to
weight gain. Several of the new, second generation APDs
are relatively expensive in comparison with conventional
APDs, as pointed out by Lindstrom (2000). Combining
typical APDs with mianserin might thus represent a more
affordable treatment strategy in some areas of the world. In
addition, by using a combination of mianserin and typical
D2 antagonists one serious side-effect of clozapine, namely
agranulocytosis, can be avoided. Tentatively, also
mirtazapine, which has a receptor affinity profile similar to
mianserin, may be used for the same purpose (Berk et al 2001).Neuropsychiatric Disease and Treatment 2005:1(4) 371
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